Role of Propafenone in the Treatment of Ventricular Premature Beats

MORRISON HODGES

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The effectiveness of propafenone versus quinidine for the therapy of ventricular premature beats was evaluated in a placebo‐controlled double‐blind parallel study. A total of 105 patients was entered; 53 patients were randomly assigned to receive propafenone (600 mg/day and 900 mg/day during low‐and high‐dose weeks, respectively) and 52 patients were randomly assigned to receive quinidine (800 mg/day and 1,600 mg/day, respectively). Both drugs significantly reduced ventricular ectopy at both dose levels; there was no statistically significant difference between the two drugs in effectiveness, although a higher percentage of patients responded to propafenone. Side effects resulting in discontinuation of therapy were more common with quinidine. This study confirms the effectiveness of propafenone in the therapy of ventricular premature beats.

Original languageEnglish (US)
Pages (from-to)536-542
Number of pages7
JournalJournal of Electrophysiology
Volume1
Issue number6
DOIs
StatePublished - Dec 1987

Keywords

  • multicenter study
  • propafenone
  • quinidine
  • randomized trial
  • ventricular arrhythmias

Fingerprint Dive into the research topics of 'Role of Propafenone in the Treatment of Ventricular Premature Beats'. Together they form a unique fingerprint.

Cite this